Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03826693 · ClinicalTrials.gov registry record · Phase 2

Efficacy of Nitrous Oxide in OCD: Pilot Study

A Phase 2 study of Obsessive - Compulsive Disorder, sponsored by Stanford University.

Recruiting
Registry status
Phase 2
Development phase
45
Enrollment target
1
Study location

NCT03826693 is a Phase 2 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Stanford University. The registered enrollment target is 45 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03826693, a Phase 2 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
Phase 2
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.

Interventions

  • DRUG Nitrous Oxide
  • DRUG Nitrogen

Study Locations (1)

California

  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2021-04-17
Est. Completion 2027-10
Phase Phase 2

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT03826693

The ClinicalTrials.gov registry entry for NCT03826693 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Nitrous Oxide is the first listed.

NCT03826693 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03826693 about?

NCT03826693 is a clinical study titled "Efficacy of Nitrous Oxide in OCD: Pilot Study". This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.

What is the current status of trial NCT03826693?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2021-04-17. Estimated completion is 2027-10.

What conditions does trial NCT03826693 study?

This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.

What interventions are being tested in trial NCT03826693?

The interventions under investigation include: Nitrous Oxide (DRUG), Nitrogen (DRUG).

Who is sponsoring clinical trial NCT03826693?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03826693 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obsessive - Compulsive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.